-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

509.O1.6 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Biology to Therapeutics

Symposia: Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, autoimmune disorders, Acute Myeloid Malignancies, AML, Translational Research, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, MPN, Clinical Research, Genetic Disorders, genomics, drug development, hematopoiesis, Chronic Myeloid Malignancies, Diseases, Immune Disorders, Therapies, registries, metabolism, white blood cell disorders, Biological Processes, Myeloid Malignancies, molecular biology
Sunday, December 11, 2022: 9:30 AM-11:00 AM
260-262 (Ernest N. Morial Convention Center)
Moderators:
Emma M. Groarke, MD, National Institutes of Health and Lucy C. Fox, MBBS, Epworth Health Care
Disclosures:
No relevant conflicts of interest to declare.
9:30 AM

Richard A Voit, MD, PhD1,2,3, Xiaotian Liao1,2,3*, Blake Cohen1,2,3*, Myriam Armant, PhD3*, Elena Kamal2,3*, Mei-Mei Huang, PhD3*, William Clarke, MD3*, David A. Williams, MD1,3, Akiko Shimamura, MD, PhD1,3* and Vijay G. Sankaran, MD, PhD1,2,3

1Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
2Broad Institute, Cambridge, MA
3Boston Children's Hospital, Boston, MA

9:45 AM

William Mannherz, BS1,2,3,4* and Suneet Agarwal, MD, PhD1,2,3,4

1Hematology/Oncology, Boston Children's Hospital, Boston, MA
2Harvard Medical School, Boston, MA
3Dana-Farber Cancer Institute, Boston, MA
4Harvard Stem Cell Institute, Boston, MA

10:00 AM

Carolin Escherich, MD1, Wenan Chen, PhD2*, Satoshi Miyamoto, MD3*, Yui Namikawa3*, Wenjian Yang, PhD4*, David T. Teachey, MD5, Zhenhua Li6*, Elizabeth A. Raetz, MD7, Eric C Larsen, MD8*, Meenakshi Devidas, PhD9*, Paul L. Martin, MD, PhD10, W Paul Bowman11*, Gang Wu, PhD2*, Ching-Hon Pui, MD12, Stephen P. Hunger, MD13, Masatoshi Takagi3, Jun J. Yang, PhD4 and Mignon L. Loh, MD14

1Department of Pharmaceutical Sciences, St. Jude Children’S Research Hospital, Memphis, TN
2Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN
3Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan
4Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN
5Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Rutledge, PA
6Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN
7Division of Pediatric Hematology and Oncology, Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders, NYU Langone Health, New York, NY
8Department of Pediatrics, Maine Children's Cancer Program, Scarborough, ME
9Department of Global Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, TN
10Division of Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, NC
11Department of Pediatrics, Cook Children's and UNT Health Science Center, Fort Worth, TX
12Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
13Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
14Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of California Benioff Children’s Hospital, Seattle, WA

10:15 AM

Piers Blombery, MBBS1,2, Vahid Pazhakh, PhD3,4*, Adriana Albuquerque5*, Jesmeen Maimaris5*, Lingge Tu4*, Brenda Briones4*, Florence Evans5*, Ella Thompson, PhD, BSc2,3*, Ben Carpenter, PhD6*, Julie Curtin7, Jonathan Lambert, BmedSci, PhD, FRCP, FRCPath6,8*, Siobhan Burns5,9* and Graham John Lieschke, PhD, MBBS, FRACP3,4

1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
2University of Melbourne, Melbourne, Australia
3Clinical Haematology, Peter MacCallum Cancer Centre/Royal Melbourne Hospital, Melbourne, Australia
4Australian Regenerative Medicine Institute, Monash University, Melbourne, Australia
5Institute of Immunity and Transplantation, University College London, London, United Kingdom
6Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
7The Children's Hospital at Westmead, Sydney, NSW, Australia
8Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom
9Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom

10:30 AM

Maksim Klimiankou, PhD1*, Sergey Kandabarau2*, Cornelia Zeidler, MD3*, Ingeborg Steiert2*, Denys Pogozhykh, PhD3*, David C. Dale, MD4, Karl Welte, Professor of Pediatrics, MD5 and Julia Skokowa, MD, PhD1

1Department of Hematology, Oncology, Clinical Immunology, University Hospital Tuebingen, Tuebingen, Germany
2Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology, Rheumatology, University Hospital Tuebingen, Tuebingen, Germany
3SCNIR, Hannover Medical School, Hannover, Germany
4Department of Medicine, University of Washington, Seattle, WA
5Pediatric Hematology and Oncology, University Children Hospital Tuebingen, Tuebingen, Germany

10:45 AM

Nathan Jayne, BSc1,2, Mengdan Liu, BA1,3, Benson Chen, PhD4*, Zhengyu Liang, PhD4*, Do-Hwan Lim, PhD4*, Bing Ren, PhD1,4*, Xiang-Dong Fu, PhD1,4* and Dong-Er Zhang, PhD1,2,4

1School of Biological Sciences, University of California, San Diego, La Jolla, CA
2Moores Cancer Center, University of California, San Diego, La Jolla, CA
3Moores Cancer Center, University of California, San Diego, SAN DIEGO, CA
4School of Medicine, University of California, San Diego, La Jolla, CA

*signifies non-member of ASH